Trial Profile
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients With Episodic Migraine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 14 Aug 2018 Results published in the Headache.
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 01 Jan 2018 Safety results published in the Cephalalgia